Pulmonary embolism is a potentially fatal condition that encountered in practice and mandates prompt identification and management. If left untreated, a delay in diagnosis can be catastrophic for the patient and carry a significant risk of death.

Polycythemia vera (PV) associated pruritus is recognized as the most excruciating aspect of the disease. However, knowledge of pathophysiology, frequency, and precise character of PV-associated pruritus is limited. Ruxolitinib presented an encouraging and promising outcome in managing PV-related pruritus, especially in patients with symptoms refractory to other treatment modalities.